Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD
NCT ID: NCT04781972
Last Updated: 2025-10-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
30 participants
INTERVENTIONAL
2021-07-27
2029-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multimodal Brain Imaging of Methylphenidate in Children and Adolescents With ADHD
NCT06077669
Investigating the Impact of Methylphenidate on Neural Response in Disruptive Behavioral Disorder
NCT02247986
EEG-MRI Imaging of Methylphenidate Effects in Adult ADHD and Attentional Symptoms in Mood Disorders
NCT05832489
Dopaminergic Modulation of Brain Activation Using Simultaneous PET/Pharmacological MRI
NCT03326245
Impact of Stimulants and In-Scanner Motion on Attentive Task Performance in ADHD (ADHD_NFB)
NCT06779825
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Methylphenidate first
Single oral dose of methylphenidate (10mg or 15 mg) and then matching placebo after washout period of one week.
Methylphenidate
single dose of 10 mg or 15 mg
Placebo
Matching placebo
Placebo first
Matching placebo and then single oral dose of methylphenidate (10mg or 15 mg) after washout period of one week.
Methylphenidate
single dose of 10 mg or 15 mg
Placebo
Matching placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Methylphenidate
single dose of 10 mg or 15 mg
Placebo
Matching placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* past or current neurological disorder
* non-ADHD cause of cognitive impairment
* uncontrolled medical disorder
* head trauma with loss of consciousness in the last year or any evidence of functional impairment due to and persisting after head trauma
* having an adverse reaction to methylphenidate, or other stimulant medication
* having a contraindication to MRI
* current smoking
6 Years
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institutes of Health (NIH)
NIH
Johns Hopkins University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kristin L Bigos, PhD
Role: PRINCIPAL_INVESTIGATOR
Johns Hopkins School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Johns Hopkins School of Medicine
Baltimore, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB00276357
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.